Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.64 (
MPP
)
1,876
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of the present study was to evaluate the effect of mitochondrial inhibitors, 1-methyl-4-phenylpyridinium (
MPP
(+)) and 3-nitropropionic acid (3-NPA), on the brain production of endogenous glutamate antagonist, kynurenic acid (KYNA).
MPP
(+) and 3-NPA dose-dependently impaired the synthesis of KYNA in rat cortical slices. Enzymatic studies revealed that
MPP
(+) inhibits in a concentration-dependent manner the activity of kynurenine aminotransferase II (
KAT
II), but not the activity of kynurenine aminotransferase I (
KAT
I). 3-NPA impaired the activity of both enzymes,
KAT
I and
KAT
II. Thus,
MPP
(+)- and 3-NPA-evoked neurotoxicity may be at least partially associated with the depletion of KYNA.
...
PMID:1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats. 1221 32
